# A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Source: https://onco.cc/trials/nct05902988/  
OnCo record `nct05902988` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of VLS-1488 in non-small-cell lung cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, ovarian cancer, sarcomas and endometrial cancer, run by Volastra Therapeutics, Inc., now recruiting.

## Summary

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer is a phase 1/2 interventional study registered as NCT05902988 by Volastra Therapeutics, Inc., with 200 participants planned, started 2023-10-18 and due to reach its primary completion in 2026-06. Interventions recorded: VLS-1488.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05902988
- Phase: 1/2
- Setting: A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer
- Sponsor: Volastra Therapeutics, Inc.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT05902988: https://clinicaltrials.gov/study/NCT05902988

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)

---
JSON: https://onco.cc/api/v1/entities/nct05902988.json